AR034556A1 - Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado - Google Patents

Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado

Info

Publication number
AR034556A1
AR034556A1 ARP010104172A ARP010104172A AR034556A1 AR 034556 A1 AR034556 A1 AR 034556A1 AR P010104172 A ARP010104172 A AR P010104172A AR P010104172 A ARP010104172 A AR P010104172A AR 034556 A1 AR034556 A1 AR 034556A1
Authority
AR
Argentina
Prior art keywords
derivative
phenylalanine
prepare
pharmaceutical composition
phenylalanine derivative
Prior art date
Application number
ARP010104172A
Other languages
English (en)
Spanish (es)
Inventor
Takayuki Kawaguchi
Sumihiro Nomura
Mikiko Tsukimoto
Toshiyuki Kume
Ila Sircar
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of AR034556A1 publication Critical patent/AR034556A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
ARP010104172A 2000-08-31 2001-08-31 Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado AR034556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22912800P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
AR034556A1 true AR034556A1 (es) 2004-03-03

Family

ID=22859926

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104172A AR034556A1 (es) 2000-08-31 2001-08-31 Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado

Country Status (28)

Country Link
US (6) US7026501B2 (cg-RX-API-DMAC7.html)
EP (1) EP1315694B1 (cg-RX-API-DMAC7.html)
JP (1) JP3899022B2 (cg-RX-API-DMAC7.html)
KR (1) KR100528049B1 (cg-RX-API-DMAC7.html)
CN (1) CN1229334C (cg-RX-API-DMAC7.html)
AR (1) AR034556A1 (cg-RX-API-DMAC7.html)
AT (1) ATE292615T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001286778B2 (cg-RX-API-DMAC7.html)
BR (1) BR0113629A (cg-RX-API-DMAC7.html)
CA (1) CA2418054C (cg-RX-API-DMAC7.html)
CZ (1) CZ303460B6 (cg-RX-API-DMAC7.html)
DE (1) DE60109943T2 (cg-RX-API-DMAC7.html)
DK (1) DK1315694T3 (cg-RX-API-DMAC7.html)
ES (1) ES2240509T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052684B (cg-RX-API-DMAC7.html)
HU (1) HUP0302693A3 (cg-RX-API-DMAC7.html)
IL (2) IL154305A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03001837A (cg-RX-API-DMAC7.html)
MY (1) MY129000A (cg-RX-API-DMAC7.html)
NO (1) NO327861B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524043A (cg-RX-API-DMAC7.html)
PL (1) PL206656B1 (cg-RX-API-DMAC7.html)
PT (1) PT1315694E (cg-RX-API-DMAC7.html)
RU (1) RU2250895C2 (cg-RX-API-DMAC7.html)
SI (1) SI1315694T1 (cg-RX-API-DMAC7.html)
TW (1) TWI224587B (cg-RX-API-DMAC7.html)
WO (1) WO2002018320A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200301039B (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302653B6 (cs) 2000-08-18 2011-08-17 Ajinomoto Co., Inc. Fenylalaninové deriváty, alfa-4-integrinový antagonist, terapeutické cinidlo nebo preventivní cinidlo a farmaceutický prostredek obsahující tyto deriváty
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
KR100881647B1 (ko) 2001-04-27 2009-02-04 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로[1,5-a]피리딘 화합물 및 그 의약
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
PT1555265E (pt) * 2002-10-22 2009-05-12 Eisai R&D Man Co Ltd Compostos de 7-fenil pirazolopiridina
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014534A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
EP1660439A2 (en) 2003-08-08 2006-05-31 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
ZA200605587B (en) 2003-12-22 2008-02-27 Ajinomoto Kk Novel phenylalanine derivative
US7410971B2 (en) 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
JP4966017B2 (ja) 2004-12-20 2012-07-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 1−シクロプロピルメチル−4−[2−(3,3,5,5−テトラメチルシクロヘキシル)フェニル]ピペラジンの塩および結晶
JP2008542407A (ja) 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム 2,6キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
EP2091916A2 (en) * 2005-11-23 2009-08-26 AstraZeneca AB L-phenylalanine derivatives and their use as integrin antagonists
EP1984344B1 (en) * 2005-12-29 2012-09-26 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP1984330A1 (en) * 2006-02-09 2008-10-29 AstraZeneca AB Chemical compounds
EP2676967B1 (en) 2006-02-28 2019-08-14 Biogen MA Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
JP5504390B2 (ja) 2006-03-03 2014-05-28 バイオジェン・アイデック・エムエイ・インコーポレイテッド ナタリズマブを用いて炎症性疾患及び自己免疫疾患を治療する方法
JP5553752B2 (ja) * 2007-08-24 2014-07-16 レクシコン ファーマシューティカルズ インコーポレイテッド 4−フェニル−6−(2,2,2−トリフルオロ−1−フェニルエトキシ)ピリミジン系化合物を調製する方法
ES2396126T3 (es) 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CA2777158A1 (en) 2009-10-21 2011-04-28 Joseph Paul Adams Process for preparing a phenylalanine derivative
SG181653A1 (en) 2010-01-11 2012-07-30 Biogen Idec Inc Assay for jc virus antibodies
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2715352T (pt) 2011-05-31 2019-06-12 Biogen Ma Inc Método de avaliação do risco de lmp
WO2013126595A1 (en) * 2012-02-21 2013-08-29 Massachusetts Eye And Ear Infirmary Methods for treating corneal and conjunctival inflammation and inflammatory disorders
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4β7インテグリンの阻害のための化合物
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ, インコーポレイテッド アルファ4ベータ7インテグリンの阻害のための化合物
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
EP0728145A1 (en) 1993-11-01 1996-08-28 Ciba-Geigy Japan Limited Endothelin receptor antagonists
BR9507220A (pt) 1994-03-28 1997-09-09 Japat Ltd Antagonistas de receptores de endotelina
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP0821670A1 (en) 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
JP2002501537A (ja) 1997-05-29 2002-01-15 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのスルホンアミド類
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
ATE256699T1 (de) 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate
WO1998058902A1 (en) 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4β1MEDIATED CELL ADHESION
AU8661298A (en) 1997-07-31 1999-02-22 American Home Products Corporation Dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1133648C (zh) 1997-07-31 2004-01-07 伊兰药品公司 抑制vla-4介导的白细胞粘附的取代的苯丙氨酸型化合物
KR20010022414A (ko) 1997-07-31 2001-03-15 진 엠. 듀발 Vla-4에 의해 매개되는 백혈구 부착을 억제시키는4-아미노-페닐알라닌형 화합물
HUP0003921A3 (en) 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
AR016133A1 (es) 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
JP2001512135A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Vla−4によって媒介された白血球接着を阻害するジペプチドおよび関連化合物
IL133635A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
JP2001512136A (ja) 1997-07-31 2001-08-21 エラン・ファーマシューティカルズ・インコーポレーテッド Vla−4により仲介される白血球接着を抑制する化合物
ATE260243T1 (de) 1997-08-22 2004-03-15 Hoffmann La Roche N-aroylphenylalaninderivate
AU739511B2 (en) * 1997-08-22 2001-10-11 F. Hoffmann-La Roche Ag N-aroylphenylalanine derivatives
US6191171B1 (en) * 1997-11-20 2001-02-20 Merck & Co., Inc. Para-aminomethylaryl carboxamide derivatives
WO1999026922A1 (en) 1997-11-21 1999-06-03 Merck & Co., Inc. Substituted pyrrole derivatives as cell adhesion inhibitors
JP2001524465A (ja) 1997-11-24 2001-12-04 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害剤としての置換β−アラニン誘導体
JP2001523711A (ja) 1997-11-24 2001-11-27 メルク エンド カムパニー インコーポレーテッド 細胞接着阻害薬としての環状アミノ酸誘導体
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
WO1999064395A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
ES2220140T3 (es) 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
AU6903200A (en) * 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
AU6909300A (en) * 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1214292B1 (en) * 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
US20040198833A1 (en) 2000-08-31 2004-10-07 Bender David Michael Acetylenic sulfonamide derivatives

Also Published As

Publication number Publication date
US7026501B2 (en) 2006-04-11
WO2002018320A2 (en) 2002-03-07
DE60109943D1 (de) 2005-05-12
PL206656B1 (pl) 2010-09-30
US20100113820A1 (en) 2010-05-06
CA2418054A1 (en) 2002-03-07
JP2004507519A (ja) 2004-03-11
DE60109943T2 (de) 2006-02-09
CZ303460B6 (cs) 2012-09-26
PT1315694E (pt) 2005-07-29
KR20030059099A (ko) 2003-07-07
US7872151B2 (en) 2011-01-18
NO20030885L (no) 2003-02-25
MY129000A (en) 2007-03-30
NO327861B1 (no) 2009-10-05
SI1315694T1 (en) 2005-10-31
US7671090B2 (en) 2010-03-02
US20130289109A1 (en) 2013-10-31
EP1315694A2 (en) 2003-06-04
CN1229334C (zh) 2005-11-30
BR0113629A (pt) 2003-07-22
US20090111879A1 (en) 2009-04-30
NZ524043A (en) 2004-08-27
RU2250895C2 (ru) 2005-04-27
US20110077299A1 (en) 2011-03-31
AU8677801A (en) 2002-03-13
MXPA03001837A (es) 2003-10-15
AU2001286778B2 (en) 2005-02-10
HK1052684A1 (en) 2003-09-26
CN1449377A (zh) 2003-10-15
HUP0302693A3 (en) 2005-05-30
CZ2003487A3 (cs) 2003-06-18
WO2002018320A3 (en) 2002-06-06
EP1315694B1 (en) 2005-04-06
ZA200301039B (en) 2004-02-09
PL365668A1 (en) 2005-01-10
IL154305A (en) 2010-11-30
ES2240509T3 (es) 2005-10-16
ATE292615T1 (de) 2005-04-15
KR100528049B1 (ko) 2005-11-15
US7456217B2 (en) 2008-11-25
NO20030885D0 (no) 2003-02-25
JP3899022B2 (ja) 2007-03-28
CA2418054C (en) 2008-08-05
TWI224587B (en) 2004-12-01
HUP0302693A2 (hu) 2003-12-29
US20050282900A1 (en) 2005-12-22
HK1052684B (en) 2005-07-22
US8501809B2 (en) 2013-08-06
US20030176498A1 (en) 2003-09-18
DK1315694T3 (da) 2005-08-08
IL154305A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
AR034556A1 (es) Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado
DK0620215T3 (da) 1H-indol-3-acetamidderivater som sPLA2-inhibitorer
BR0008015A (pt) Uso de um composto, composto, composições farmacêuticas, e, processo para preparar um composto
ATE306261T1 (de) Antithrombosemittel
ATE297203T1 (de) Antithrombotische mitteln
EA200200873A1 (ru) Новые пиперазиновые производные
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
AR003966A1 (es) Un derivado de difenilmetilenpiperidina, composición farmacéutica que lo contiene, metodo de preparación de dicho derivado y uso de este ultimo para preparar un medicamento
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
RU98102392A (ru) Производные дифенилметиленпиперидина
CO4820432A1 (es) Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina
ES2058173T3 (es) Dioxialquilenaril-dihidropiridinas, productos intermedios para su fabricacion, procedimientos para su fabricacion y su utilizacion.
AR058180A1 (es) Indeno derivados, su preparacion y su uso como medicamentos
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
CA2007261A1 (en) Novel tetralin derivatives
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
DK0944618T3 (da) Nye N-benzensulfonyl-L-prolin-derivater, fremgangsmåde til deres fremstilling og deres anvendelse til terapeutiske formål
BR0314759A (pt) Derivados de pirazol
EP0138684A3 (en) 2-(n-pyrrolidino)-3-isobutoxy-n-phenyl-substituted n-benzylpropyl amines, their preparation and their pharmaceutical use
ES2055887T3 (es) Nuevos derivados de la morfolina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO5660084A1 (es) Nuevos derivados de fenilheteroalquilamina, proceso para su prepraracion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
EP1325918A4 (en) INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE
AR019664A1 (es) Composicion para el tratamiento de enfermedades del cartilago
KR890012951A (ko) 인단옥시아세트산 유도체 및 그의 제조방법

Legal Events

Date Code Title Description
FG Grant, registration